Impaired glycemia increases disease progression in mild cognitive impairment

Neurobiology of Aging

Volumn 35, Issue 3, 2014, Pages 585-589

  Morris, Jill K ^a,b   Vidoni, Eric D ^a,b   Honea, Robyn A ^a,b   Burns, Jeffrey M ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Dementia; Diabetes; Hyperglycemia; Insulin resistance

Indexed keywords

GLUCOSE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CLINICAL DEMENTIA RATING; COGNITION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DYSGLYCEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; HUMAN; IMPAIRED FASTING GLUCOSE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ALZHEIMER'S DISEASE; DEMENTIA; DIABETES; HYPERGLYCEMIA; INSULIN RESISTANCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; COGNITION; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; MILD COGNITIVE IMPAIRMENT; RISK FACTORS;

EID: 84889571471     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.09.033     Document Type: Article

References (29)

1. Alzheimer's Disease Neuroimaging Initiative. http://adni.loni.usc.edu.
2. Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., Holtzman D.M., Santacruz A., Buckles V., Oliver A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., Sperling R.A., Salloway S., Morris J.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N.Engl. J. Med. 2012, 367:795-804.
3. Bennett D.A., Wilson R.S., Schneider J.A., Evans D.A., Beckett L.A., Aggarwal N.T., Barnes L.L., Fox J.H., Bach J. Natural history of mild cognitive impairment in older persons. Neurology 2002, 59:198-205.
4. Burke W.J., Miller J.P., Rubin E.H., Morris J.C., Coben L.A., Duchek J., Wittels I.G., Berg L. Reliability of the Washington University Clinical Dementia Rating. Arch. Neurol. 1988, 45:31-32.
5. Burns J.M., Donnelly J.E., Anderson H.S., Mayo M.S., Spencer-Gardner L., Thomas G., Cronk B.B., Haddad Z., Klima D., Hansen D., Brooks W.M. Peripheral insulin and brain structure in early Alzheimer disease. Neurology 2007, 69:1094-1104.
6. Cowie C.C., Rust K.F., Byrd-Holt D.D., Eberhardt M.S., Flegal K.M., Engelgau M.M., Saydah S.H., Williams D.E., Geiss L.S., Gregg E.W. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2006, 29:1263-1268.
7. De Felice F.G. Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J.Clin. Invest. 2013, 123:531-539.
8. Fischl B., Sereno M.I., Tootell R.B., Dale A.M. High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum. Brain Mapp. 1999, 8:272-284.
9. Holland D., Brewer J.B., Hagler D.J., Fennema-Notestine C., Dale A.M. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. U S A 2009, 106:20954-20959.
10. Honea R.A., Swerdlow R.H., Vidoni E.D., Burns J.M. Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology 2011, 76:822-829.
11. Hotamisligil G.S. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005, 54(suppl 2):S73-S78.
12. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., Quon M.J. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J.Clin. Endocrinol. Metab. 2000, 85:2402-2410.
13. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., Nathan D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N.Engl. J. Med. 2002, 346:393-403.
14. Landau S.M., Harvey D., Madison C.M., Koeppe R.A., Reiman E.M., Foster N.L., Weiner M.W., Jagust W.J. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging 2011, 32:1207-1218. Alzheimer's Disease Neuroimaging Initiative.
15. Matsuzaki T., Sasaki K., Hata J., Hirakawa Y., Fujimi K., Ninomiya T., Suzuki S.O., Kanba S., Kiyohara Y., Iwaki T. Association of Alzheimer disease pathology with abnormal lipid metabolism: the Hisayama Study. Neurology 2011, 77:1068-1075.
16. Mosconi L., Mistur R., Switalski R., Brys M., Glodzik L., Rich K., Pirraglia E., Tsui W., De Santi S., de Leon M.J. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009, 72:513-520.
17. Neeland I.J., Turer A.T., Ayers C.R., Powell-Wiley T.M., Vega G.L., Farzaneh-Far R., Grundy S.M., Khera A., McGuire D.K., de Lemos J.A. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012, 308:1150-1159.
18. Petersen R.C., Stevens J.C., Ganguli M., Tangalos E.G., Cummings J.L., DeKosky S.T. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1133-1142.
19. Puglielli L., Ellis B.C., Saunders A.J., Kovacs D.M. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J.Biol. Chem. 2003, 278:19777-19783.
20. Ragogna F., Lattuada G., Ruotolo G., Luzi L., Perseghin G. Lack of association of apoE epsilon4 allele with insulin resistance. Acta Diabetol. 2012, 49:25-32.
21. Salas-Salvado J., Martinez-Gonzalez M.A., Bullo M., Ros E. The role of diet in the prevention of type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 2011, 21(suppl 2):B32-B48.
22. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann. Neurol. 2009, 65:403-413.
23. Shirk S.D., Mitchell M.B., Shaughnessy L.W., Sherman J.C., Locascio J.J., Weintraub S., Atri A. AWeb-based normative calculator for the Uniform Data Set (UDS) neuropsychological test battery. Alzheimer Res. Ther. 2011, 3:32.
24. Solomon T.P., Thyfault J.P. Type 2 diabetes sits in a chair. Diabetes Obes. Metab 2013, 15:987-992.
25. van den Kommer T.N., Dik M.G., Comijs H.C., Jonker C., Deeg D.J. Role of lipoproteins and inflammation in cognitive decline: do they interact?. Neurobiol. Aging 2012, 33:196 e1-12.
26. Velayudhan L., Poppe M., Archer N., Proitsi P., Brown R.G., Lovestone S. Risk of developing dementia in people with diabetes and mild cognitive impairment. Br. J. Psychiatry 2010, 196:36-40.
27. Viswanathan A., Rocca W.A., Tzourio C. Vascular risk factors and dementia: how to move forward?. Neurology 2009, 72:368-374.
28. Xu W., Caracciolo B., Wang H.X., Winblad B., Backman L., Qiu C., Fratiglioni L. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010, 59:2928-2935.
29. Yamashita S., Nakamura T., Shimomura I., Nishida M., Yoshida S., Kotani K., Kameda-Takemuara K., Tokunaga K., Matsuzawa Y. Insulin resistance and body fat distribution. Diabetes Care 1996, 19:287-291.